project id: TCGA-THCA; case submitter id: TCGA-EL-A3D0; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.77; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 7.3; age at index: 61; days to birth: -22622; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 22622; ajcc pathologic m: M0; ajcc pathologic n: N1b; ajcc pathologic stage: Stage III; ajcc pathologic t: T4; ajcc staging system edition: 5th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 4254.0; icd 10 code: C73; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Thyroid gland; synchronous malignancy: Not Reported; tissue or organ of origin: Thyroid gland; tumor grade: Not Reported; year of diagnosis: 2001; alcohol history: Not Reported; is ffpe: false; weight: 20.0; composition: Not Reported; days to collection: 3829; days to sample procurement: 0; initial weight: 270.0; portion submitter id: TCGA-EL-A3D0-01A-12; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 50.0; percent tumor cells: 40.0; percent tumor nuclei: 65.0;